Top

Published in:

Open Access 01-07-2016 | Endocrine Genetics/Epigenetics

Glucocorticoid receptor polymorphisms modulate cardiometabolic risk factors in patients in long-term remission of Cushing’s syndrome

Authors: Sean H. P. P. Roerink, M. A. E. M. Wagenmakers, J. W. A. Smit, E. F. C. van Rossum, R. T. Netea-Maier, T. S. Plantinga, A. R. M. M. Hermus

Published in: Endocrine | Issue 1/2016

Abstract

Context

Glucocorticoid receptor (GR) polymorphisms modulate glucocorticoid (GC) sensitivity and are associated with altered metabolic profiles.

Objective

To evaluate the presence of GR polymorphisms (BclI (rs41423247), N363S (rs56149945), ER22/23EK (rs6189/rs6190), and 9β (rs6198) and investigate their associations with metabolic alterations in patients in long-term remission of Cushing’s syndrome (CS).

Design and setting

Cross-sectional case–control study.

Patients and methods

Sixty patients in long-term remission of CS were genotyped. Associations between GR polymorphisms and multiple vascular, body composition and metabolic parameters were investigated.

Main outcome measures

Allelic frequencies of the polymorphisms and their associations with several cardiometabolic risk factors.

Results

This study shows that carriers of the 9β polymorphism have a higher systolic blood pressure and lower resistin levels. The GC sensitizing BclI polymorphism is associated with an adverse cardiometabolic risk factor profile: higher fat percentages of extremities and legs, higher serum leptin and E-selectin levels, and higher intima media thickness in carriers versus non-carriers.

Conclusions

The 9β and BclI polymorphisms of the GR adversely affect the cardiometabolic profile in patients who are in remission after the treatment of CS. This suggests that genetically altered GC sensitivity modulates the long-term adverse cardiometabolic effects resulting from (endogenous) hypercortisolism.

J. Lindholm, S. Juul, J.O. Jorgensen, J. Astrup, P. Bjerre, U. Feldt-Rasmussen, C. Hagen, J. Jorgensen, M. Kosteljanetz, L. Kristensen, P. Laurberg, K. Schmidt, J. Weeke, Incidence and late prognosis of cushing’s syndrome: a population-based study. J. Clin. Endocrinol. Metab. 86(1), 117–123 (2001)PubMed

G. Arnaldi, A. Angeli, A.B. Atkinson, X. Bertagna, F. Cavagnini, G.P. Chrousos, G.A. Fava, J.W. Findling, R.C. Gaillard, A.B. Grossman, B. Kola, A. Lacroix, T. Mancini, F. Mantero, J. Newell-Price, L.K. Nieman, N. Sonino, M.L. Vance, A. Giustina, M. Boscaro, Diagnosis and complications of Cushing’s syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 88(12), 5593–5602 (2003)CrossRefPubMed

M. Wagenmakers, S. Roerink, L. Gil, T. Plantinga, J. Smit, R. Netea-Maier, A. Hermus, Persistent centripetal fat distribution and metabolic abnormalities in patients in long-term remission of Cushing’s syndrome. Clin. Endocrinol. 82(2), 180–187 (2015). doi:10.1111/cen.12639 CrossRef

M.J. Barahona, N. Sucunza, E. Resmini, J.M. Fernandez-Real, W. Ricart, J.M. Moreno-Navarrete, T. Puig, J. Farrerons, S.M. Webb, Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing’s syndrome. J. Clin. Endocrinol. Metab. 94(9), 3365–3371 (2009). doi:10.1210/jc.2009-0766 CrossRefPubMed

A. Colao, R. Pivonello, S. Spiezia, A. Faggiano, D. Ferone, M. Filippella, P. Marzullo, G. Cerbone, M. Siciliani, G. Lombardi, Persistence of increased cardiovascular risk in patients with Cushing’s disease after five years of successful cure. J. Clin. Endocrinol. Metab. 84(8), 2664–2672 (1999). doi:10.1210/jcem.84.8.5896 PubMed

N.A. Huizenga, J.W. Koper, P. de Lange, H.A. Pols, R.P. Stolk, D.E. Grobbee, F.H. de Jong, S.W. Lamberts, Interperson variability but intraperson stability of baseline plasma cortisol concentrations, and its relation to feedback sensitivity of the hypothalamo-pituitary-adrenal axis to a low dose of dexamethasone in elderly individuals. J. Clin. Endocrinol. Metab. 83(1), 47–54 (1998)PubMed

E.F. van Rossum, S.W. Lamberts, Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition. Recent Prog. Horm. Res. 59, 333–357 (2004)CrossRefPubMed

N.A. Huizenga, J.W. Koper, P. De Lange, H.A. Pols, R.P. Stolk, H. Burger, D.E. Grobbee, A.O. Brinkmann, F.H. De Jong, S.W. Lamberts, A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J. Clin. Endocrinol. Metab. 83(1), 144–151 (1998)PubMed

A.M. Di Blasio, E.F. van Rossum, S. Maestrini, M.E. Berselli, M. Tagliaferri, F. Podesta, J.W. Koper, A. Liuzzi, S.W. Lamberts, The relation between two polymorphisms in the glucocorticoid receptor gene and body mass index, blood pressure and cholesterol in obese patients. Clin. Endocrinol. 59(1), 68–74 (2003)CrossRef

10.

E.F. van Rossum, J.W. Koper, A.W. van den Beld, A.G. Uitterlinden, P. Arp, W. Ester, J.A. Janssen, A.O. Brinkmann, F.H. de Jong, D.E. Grobbee, H.A. Pols, S.W. Lamberts, Identification of the BclI polymorphism in the glucocorticoid receptor gene: association with sensitivity to glucocorticoids in vivo and body mass index. Clin. Endocrinol. 59(5), 585–592 (2003)CrossRef

11.

E.F. van Rossum, J.W. Koper, N.A. Huizenga, A.G. Uitterlinden, J.A. Janssen, A.O. Brinkmann, D.E. Grobbee, F.H. de Jong, C.M. van Duyn, H.A. Pols, S.W. Lamberts, A polymorphism in the glucocorticoid receptor gene, which decreases sensitivity to glucocorticoids in vivo, is associated with low insulin and cholesterol levels. Diabetes 51(10), 3128–3134 (2002)CrossRefPubMed

12.

E.F. van Rossum, P.G. Voorhoeve, S.J. te Velde, J.W. Koper, H.A. Delemarre-van de Waal, H.C. Kemper, S.W. Lamberts, The ER22/23EK polymorphism in the glucocorticoid receptor gene is associated with a beneficial body composition and muscle strength in young adults. J. Clin. Endocrinol. Metab. 89(8), 4004–4009 (2004). doi:10.1210/jc.2003-031422 CrossRefPubMed

13.

R.H. Oakley, C.M. Jewell, M.R. Yudt, D.M. Bofetiado, J.A. Cidlowski, The dominant negative activity of the human glucocorticoid receptor beta isoform. Specificity and mechanisms of action. J. Biol. Chem. 274(39), 27857–27866 (1999)CrossRefPubMed

14.

R.H. Oakley, M. Sar, J.A. Cidlowski, The human glucocorticoid receptor beta isoform. Expression, biochemical properties, and putative function. J. Biol. Chem. 271(16), 9550–9559 (1996)CrossRefPubMed

15.

E.L. van den Akker, H. Russcher, E.F. van Rossum, A.O. Brinkmann, F.H. de Jong, A. Hokken, H.A. Pols, J.W. Koper, S.W. Lamberts, Glucocorticoid receptor polymorphism affects transrepression but not transactivation. J. Clin. Endocrinol. Metab. 91(7), 2800–2803 (2006). doi:10.1210/jc.2005-2119 CrossRefPubMed

16.

A.A. Syed, J.A. Irving, C.P. Redfern, A.G. Hall, N.C. Unwin, M. White, R.S. Bhopal, J.U. Weaver, Association of glucocorticoid receptor polymorphism A3669G in exon 9beta with reduced central adiposity in women. Obesity 14(5), 759–764 (2006). doi:10.1038/oby.2006.86 CrossRefPubMed

17.

E.L. van den Akker, J.W. Koper, E.F. van Rossum, M.J. Dekker, H. Russcher, F.H. de Jong, A.G. Uitterlinden, A. Hofman, H.A. Pols, J.C. Witteman, S.W. Lamberts, Glucocorticoid receptor gene and risk of cardiovascular disease. Arch. Intern. Med. 168(1), 33–39 (2008). doi:10.1001/archinternmed.2007.41 CrossRefPubMed

18.

L. Trementino, G. Appolloni, C. Concettoni, M. Cardinaletti, M. Boscaro, G. Arnaldi, Association of glucocorticoid receptor polymorphism A3669G with decreased risk of developing diabetes in patients with Cushing’s syndrome. Eur.J. Endocrinal. 166(1), 35–42 (2012). doi:10.1530/EJE-11-0722 CrossRef

19.

A. Szappanos, A. Patocs, J. Toke, B. Boyle, M. Sereg, J. Majnik, G. Borgulya, I. Varga, I. Liko, K. Racz, M. Toth, BclI polymorphism of the glucocorticoid receptor gene is associated with decreased bone mineral density in patients with endogenous hypercortisolism. Clin. Endocrinol. 71(5), 636–643 (2009). doi:10.1111/j.1365-2265.2009.03528.x CrossRef

20.

O. Ragnarsson, C. Glad, P. Berglund, R. Bergthorsdottir, D.N. Eder, G. Johannsson, Common genetic variants in the glucocorticoid receptor and the 11beta-Hydroxysteroid dehydrogenase type 1 genes influence long-term cognitive impairments in patients with Cushing’s syndrome in remission. J. Clin. Endocrinol. Metab. (2014). doi:10.1210/jc.2014-1906

21.

L.K. Nieman, B.M. Biller, J.W. Findling, J. Newell-Price, M.O. Savage, P.M. Stewart, V.M. Montori, The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 93(5), 1526–1540 (2008). doi:10.1210/jc.2008-0125 CrossRefPubMedPubMedCentral

22.

M.E. Molitch, D.R. Clemmons, S. Malozowski, G.R. Merriam, S.M. Shalet, M.L. Vance, S. Endocrine Society’s Clinical Guidelines, P.A. Stephens, Evaluation and treatment of adult growth hormone deficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 91(5), 1621–1634 (2006). doi:10.1210/jc.2005-2227

23.

W. Arlt, B. Allolio, Adrenal insufficiency. Lancet 361(9372), 1881–1893 (2003). doi:10.1016/S0140-6736(03)13492-7 CrossRefPubMed

24.

D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, R.C. Turner, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7), 412–419 (1985)CrossRefPubMed

25.

R. Pivonello, A. Faggiano, G. Lombardi, A. Colao, The metabolic syndrome and cardiovascular risk in Cushing’s syndrome. Endocrinol. Metab. Clin. North Am. 34(2), 327–339 (2005). doi:10.1016/j.ecl.2005.01.010. viii CrossRefPubMed

26.

B.L. Wajchenberg, D. Giannella-Neto, M.E. da Silva, R.F. Santos, Depot-specific hormonal characteristics of subcutaneous and visceral adipose tissue and their relation to the metabolic syndrome. Horm Metab Res 34(11–12), 616–621 (2002). doi:10.1055/s-2002-38256 CrossRefPubMed

27.

O. Ragnarsson, C.A. Glad, R. Bergthorsdottir, E.G. Almqvist, E. Ekerstad, H. Widell, B. Wangberg, G. Johannsson, Body composition and bone mineral density in women with Cushing’s syndrome in remission and the association with common genetic variants influencing glucocorticoid sensitivity. Eur. J. Endocrinol. 172(1), 1–10 (2015). doi:10.1530/EJE-14-0747 CrossRefPubMed

28.

Y.X. Yan, J. Dong, J. Zhang, F. Liu, W. Wang, L. Zhang, Y. He, Polymorphisms in NR3C1 gene associated with risk of metabolic syndrome in a Chinese population. Endocrine 47(3), 740–748 (2014). doi:10.1007/s12020-014-0324-9 CrossRefPubMed

Title: Glucocorticoid receptor polymorphisms modulate cardiometabolic risk factors in patients in long-term remission of Cushing’s syndrome
Authors: Sean H. P. P. Roerink
M. A. E. M. Wagenmakers
J. W. A. Smit
E. F. C. van Rossum
R. T. Netea-Maier
T. S. Plantinga
A. R. M. M. Hermus
Publication date: 01-07-2016
Publisher: Springer US
Published in: Endocrine / Issue 1/2016
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-016-0883-z

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Glucocorticoid receptor polymorphisms modulate cardiometabolic risk factors in patients in long-term remission of Cushing’s syndrome

Abstract

Context

Objective

Design and setting

Patients and methods

Main outcome measures

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Context

Objective

Design and setting

Patients and methods

Main outcome measures

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

Elevated circulating levels of betatrophin are associated with polycystic ovary syndrome

Serum thyrotropin level of 30 μIU/mL is inadequate for preablative thyroglobulin to serve as a prognostic marker for differentiated thyroid cancer

GALNT2 mRNA levels are associated with serum triglycerides in humans

Blood glucose fluctuation accelerates renal injury involved to inhibit the AKT signaling pathway in diabetic rats

Molecular profiles of cancer stem-like cell populations in aggressive thyroid cancers

Non-functioning pituitary adenomas: growth and aggressiveness

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page